⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S3 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells

Tressie A. Posey Joan Jacob Ashlyn Parkhurst Shraddha Subramanian Liezl E. Francisco Zhengdong Liang Kendra S. Carmon

View at Publisher

Ask AI

Bookmark

Share

Abstract

shows cytotoxicity of inhibitors of MET, STAT3, and Wnt in CTL and LGR5 KD/KO CRC cells

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Posey et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db64358752388c https://doi.org/10.1158/1535-7163.27035764.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
2Figure S1 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
3Figure S5 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
4Figure S4 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
5Figure S6 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024

Data from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
Figure S4 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer2024
Figure S1 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer2024